Fri, Dec 19, 2014, 4:06 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

  • fritzdutchrio fritzdutchrio Nov 7, 2013 1:27 PM Flag

    Investors finally figuring out this stock is worth $23 a share..get behind it people before the run... Amgen..

    is behind this stock full bore. you should be too!!! look what CLDX did and those who sold too soon!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Read this message on another board. Allow me to share.

      james08099 • Oct 21, 2013 12:00 PM Flag
      0users liked this postsusers disliked this posts1Reply
      RAJ! Check out CYTK it is the next ACAD
      CYTK presents the same misunderstanding as ACAD. ACAD, if anyone remembers failed their first phase three bc the 10mg and the 40 mg pimavaserin were combined in the same study, but it was only the 40 mg dosage that had a effect on the very sick Parkinson's patients. That misunderstanding caused acad to plummet under $1, until the second phase 3 trial was preformed. Like ACAD, CYTK has a drug that is more effective at a higher dosage and when the lower doses are cut from the phase 3 study, it will show significance. It is these misunderstandings that create opportunities. Been in Rockwell since $3 with Raj and ACAD at $2. This is the next one to move. Everyone should check it out Less

 
CYTK
4.890.00(0.00%)3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.